Jeb Keiper
About Jeb Keiper
Jeb Keiper is the CEO of Nimbus Therapeutics and has held various leadership roles in the pharmaceutical industry, including positions at GlaxoSmithKline and McKinsey & Co. He holds multiple degrees from MIT and has significant experience in business development and strategic operations.
Current Role at Nimbus Therapeutics
Jeb Keiper serves as the CEO of Nimbus Therapeutics, a position he has held since 2018. Under his leadership, Nimbus Therapeutics has focused on advancing its drug discovery platform and developing innovative therapies. His tenure has been marked by significant financial achievements, including securing over $775 million in partnerships and financing from 2014 to 2018. Keiper's experience in the pharmaceutical industry contributes to the strategic direction of the company.
Previous Experience at GlaxoSmithKline
Jeb Keiper held multiple roles at GlaxoSmithKline (GSK) from 2005 to 2014. He began as Director of R&D Executive Operations, where he managed research and development processes. He then transitioned to Head of Acquisitions and Divestitures, overseeing strategic transactions. Additionally, he served as VP of Business Development for GSK Oncology, where he led significant initiatives, including the GSK-Novartis business swap valued at $16 billion in 2014.
Educational Background
Jeb Keiper holds four degrees from the Massachusetts Institute of Technology (MIT). He earned a Bachelor of Science in Chemistry and a Master of Science in Chemical Engineering, followed by an MBA from the MIT Sloan School of Management. His academic background in finance, marketing, and entrepreneurship complements his extensive experience in the pharmaceutical industry.
Board Memberships and Current Affiliations
In addition to his role at Nimbus Therapeutics, Jeb Keiper is a board member at ROME Therapeutics and Cardurion Pharmaceuticals, both based in Cambridge, Massachusetts. He has been involved with ROME Therapeutics since 2019 and was elected to the board of Cardurion Pharmaceuticals in June 2018. His participation in these organizations reflects his commitment to advancing healthcare and pharmaceutical innovation.
Career Progression and Early Roles
Jeb Keiper began his career as a bench chemist at Pfizer R&D, where he worked as a Scientist I in Pharmaceutical Sciences. He later transitioned to consulting at McKinsey & Co., serving as a Business Analyst and then as an Engagement Manager. His diverse experience in both scientific and business roles has equipped him with a unique perspective in the pharmaceutical sector.